Toxicology Report

Science-backed ERA derivation by certified toxicologists with ex-agency experts -

Cemiplimab

Drug Overview

What is Cemiplimab?

Cemiplimab is a biological material, macromolecule, organism-derived product, or complex preparation rather than a conventional small-molecule chemical. A human monoclonal antibody targeting PD-1, used in various cancers. Its defining characteristics depend on biological origin, molecular or cellular composition, processing, and storage. Identity and quality are therefore established with source documentation and appropriate biochemical, microbiological, immunological, or potency tests instead of relying only on a CAS number or simple molecular formula.

Biological activity depends on the intact biological entity or macromolecular composition, processing method, dose, and route of exposure; it cannot be reduced safely to the mechanism of one small molecule unless a specific active component is identified. Major applications include biomedical or diagnostic research, regulated biological preparations where applicable, identity and potency testing, manufacturing quality control, and biosafety or environmental assessment.

Masuu Global provides end-to-end Environmental Risk Assessment (ERA) support for pharmaceutical and healthcare products, covering Phase I environmental exposure assessment, Phase II environmental fate and effects assessment, data-gap analysis, testing strategy, laboratory coordination and final regulatory-ready reporting.

Monograph Inquiry

Request Your Assessment

Add this compound to your inquiry list and our team will follow up with full documentation, pricing, and licensing terms.

View Inquiry List →
What's included:
ERA Phase I Evaluation, ERA Phase II Evaluation, Consortium Testing Support (OECD Ecotoxicology Study)
1,500+
Environmental & Regulatory
Risk Assessments Supported
70+
Subject Matter Experts
across global operations
12
In-House Ex-Agency
Regulatory & Scientific Experts
3
Expert Credentials:
ERT · UKRT · DABT

Regulatory Framework

Assessment Methodology

Masuu Global follows a science-based, tiered and risk-based ERA methodology, aligned with applicable international regulatory requirements. For human medicinal products, our approach is primarily guided by the EMA Guideline EMEA/CHMP/SWP/4447/00 Rev. 1, effective 1 September 2024, together with relevant OECD Test Guidelines and regional regulatory requirements.

EMA
ERA

EMA — Environmental Risk Assessment

Assessment of potential environmental exposure associated with the use, manufacture and disposal of medicinal products, with a structured approach to determine whether further environmental assessment is required.

Phase
I

Phase I — Environmental Exposure Assessment

Initial screening to determine potential environmental exposure, covering PEC calculation, physicochemical properties, usage and dosage data, environmental entry pathways, and persistence and fate considerations.

Phase
II

Phase II — Environmental Fate & Effects Assessment

Where Phase I indicates further assessment is required, Phase II provides detailed evaluation of environmental fate, persistence and ecological effects — including biodegradation, bioaccumulation, aquatic toxicity, PNEC derivation and PEC/PNEC risk characterisation.

OECD
GLP

OECD & International Testing Principles

Where laboratory studies are required, testing strategies are designed with consideration of relevant OECD Test Guidelines, GLP expectations and applicable regulatory requirements.

Risk
Env

Risk-Based Environmental Assessment

Integration of physicochemical data, environmental fate information, ecotoxicological data, existing literature, published studies, regulatory databases, usage data, and environmental monitoring data.

WoE

Weight-of-Evidence (WoE) Approach

A scientifically justified WoE approach integrates existing data and avoids unnecessary testing wherever scientifically and regulatorily justified.

ERA Assessment Pathway

Phase I → Phase II → Risk Characterization

Each phase builds on the prior tier — screening first, escalating only when the evidence demands it.

Phase I Screening

Environmental Exposure Assessment

Initial screening to determine whether the substance requires progression to Phase II.

  • Product and substance information review
  • Indication, dose and usage assessment
  • PEC calculation and environmental exposure estimation
  • Physicochemical property review
  • Initial environmental risk screening
  • Determination of Phase II requirement
Phase II Evaluation

Environmental Fate & Effects

Detailed evaluation when Phase I triggers further assessment.

  • Biodegradation, hydrolysis & photolysis
  • Adsorption/desorption behaviour
  • Bioaccumulation potential
  • Algal, Daphnia and fish toxicity
  • Chronic ecotoxicity, where required
  • PEC/PNEC risk characterisation
Consortium Testing Model

Laboratory Coordination & Study Execution

When regulatory testing is mandatory, Masuu coordinates with qualified GLP/appropriate testing laboratories and specialized scientific partners — giving clients a single point of contact across the full testing lifecycle.

Study Selection→ Protocol Development→ Lab Coordination→ Sample Management→ Study Execution→ Data Review→ Regulatory Interpretation→ ERA Integration

Final ERA Report — Contents

  • Executive summary
  • Substance & product information
  • Environmental exposure assessment
  • Phase I evaluation
  • Phase II assessment (where applicable)
  • Environmental fate assessment
  • Ecotoxicological assessment
  • PEC/PNEC calculations
  • Risk characterisation
  • Data gap evaluation
  • Testing rationale
  • Risk mitigation considerations
  • References and supporting scientific evidence

How We Work

Report Preparation Process

Every ERA follows a structured, tiered workflow designed to deliver scientifically defensible and regulator-ready assessments.

01

Comprehensive Data Collection

Product, substance, usage, physicochemical, toxicological, environmental and regulatory information collected and reviewed.

02

Phase I Environmental Screening

Environmental exposure assessment and determination of whether the assessment can conclude at Phase I or requires progression.

03

Phase II Evaluation

Detailed environmental fate and ecotoxicological assessment when Phase II is triggered.

04

Data Gap & Testing Strategy

Missing information identified and available alternatives evaluated before recommending additional testing.

05

Consortium Testing Support

Where testing is mandatory, Masuu coordinates with qualified testing partners through its Consortium Model.

06

Scientific & Regulatory Review

Integration and critical review of generated and existing data by experienced scientific and regulatory experts.

07

Final ERA Delivery

Comprehensive ERA report with transparent methodology, scientific rationale, calculations, conclusions and regulatory recommendations.

Ex-Agency Advantage

Why Masuu Global?

Our experienced regulatory and scientific experts bring a practical regulatory perspective — helping clients understand not only what data are required, but why they are required and how regulators may evaluate them.

✓
Regulatory expectation-driven assessmentsAligned with applicable global ERA requirements.
✓
Tiered assessment strategyPhase I screening followed by Phase II only when scientifically and regulatorily justified.
✓
Data gap optimisationLiterature, databases, read-across and in-silico information evaluated before recommending new testing.
✓
Consortium testing coordinationManaged laboratory engagement when mandatory studies are required.
✓
Integrated scientific interpretationEnvironmental fate, ecotoxicity and risk characterisation connected into one coherent assessment.
✓
Regulatory-ready documentationDesigned to support submissions, authority queries and technical reviews.
✓
Reduced testing burdenStructured data-gap and weight-of-evidence approach minimises unnecessary study requirements.
✓
Single-point coordinationAssessment, testing strategy, laboratory engagement and final ERA integration — one team.
✓
Global regulatory supportERA services spanning pharmaceutical and healthcare products across multiple markets.

Ready to request your assessment?

Add this compound to your inquiry list, or browse our full database of 7,000+ molecules.

Book a Demo